Evidence map›Paper›PMID 37985504›Full record

ArticleArchives of osteoporosis2023

Reducing the risk of denosumab-induced hypocalcemia in patients with advanced chronic kidney disease: a quality improvement initiative.

Tharsan Kanagalingam, Tayyab Khan, Nabil Sultan, Andrea Cowan, Jenny Thain, Cindy Hoy, Seadna Ledger, Kristin K Clemens

Abstract read
PubMed Publisher
In one paragraph

Article in Archives of osteoporosis, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Tharsan KanagalingamSchulich School of Medicine and Dentistry, Western University, London, ON, Canada.
Tayyab KhanSchulich School of Medicine and Dentistry, Western University, London, ON, Canada.
Nabil SultanSchulich School of Medicine and Dentistry, Western University, London, ON, Canada.
Andrea CowanSchulich School of Medicine and Dentistry, Western University, London, ON, Canada.
Jenny ThainSchulich School of Medicine and Dentistry, Western University, London, ON, Canada.
Cindy HoySt Joseph's Health Care London, London, ON, Canada.
Seadna LedgerLondon Health Sciences Centre, London, ON, Canada.
Kristin K ClemensSchulich School of Medicine and Dentistry, Western University, London, ON, Canada. kristin.clemens@sjhc.london.on.ca.
Western University · CALondon Health Sciences Centre · CASt Joseph's Health Care · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Denosumab can improve bone health in advanced kidney disease (CKD) but is associated with hypocalcemia. We created a clinical care pathway focused on the safe provision of denosumab in advanced CKD that reduced the risk of hypocalcemia by 37% at our hospital. Similar pathways could be adopted and tested in other centers. PURPOSE: There is an increased risk of hypocalcemia with denosumab in advanced chronic kidney disease (CKD). We aimed to reduce the proportion of patients with advanced CKD who experienced denosumab-induced hypocalcemia at our center.

methodsWe conducted a quality improvement (QI) project of patients with CKD stage 3b or less (i.e., estimated glomerular filtration rate <45 mL/min/1.73m

resultsThere were 6 patients with advanced CKD treated with denosumab prior to the implementation of our care pathway (March 2015-October 2020; 83% receiving dialysis). At the time of their denosumab injection, 83% were using 500-1000 mg of calcium, and 83% used 1000-2000 IU of vitamin D

conclusionsA clinical care pathway focused on the safe provision of denosumab in advanced CKD reduced the risk of hypocalcemia in patients treated in our hospital. Similar pathways could be adopted and tested in other centers.

Indexed as

Bone Density Conservation AgentsHypercalcemiaHyperphosphatemiaHypocalcemiaRenal Insufficiency, ChronicCalciumCholecalciferolDenosumabHumansQuality ImprovementBone Density Conservation AgentsCalciumCholecalciferolDenosumabChronic kidney diseaseDenosumabDialysisHypocalcemiaOsteoporosis

Identifiers

PMID37985504
OpenAlexW4388849772

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.